If you have diabetes, your doctor might suggest Basaglar (insulin glargine) as a treatment option for you. It’s a prescription drug used to treat: type 1 diabetes in adults and children ages 6 years ...

The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 ...

The U.S. Food and Drug Administration on Wednesday approved Eli Lilly & Co's diabetes drug Basaglar, a cheaper version of Sanofi AG's top-selling drug Lantus. The drug, an injection known also as ...

Eli Lilly and Boehringer Ingelheim announced the launch of Basaglar (insulin glargine injection) for use to control high blood sugar in children and adults with type 1 diabetes and adults with type 2 ...

Original Medicare (Part A and Part B) does not cover insulin glargine (Basagalar). Medicare Part C and Part D cover some forms of insulin if you have diabetes, but coverage depends on the plan‘s ...

FDA Issues Complete Response Letter for Diabetes Drug The FDA has approved Basaglar (insulin glargine; Eli Lilly and Boehringer Ingelheim) injection to improve glycemic control in pediatric patients ...

Basaglar, which is considered a biosimilar of Sanofi’s blockbuster diabetes drug Lantus in the EU but not the US, has the same amino acid sequence as the currently marketed insulin glargine product, ...

Eli Lilly and Boehringer Ingelheim launched Basaglar, a biosimilar referencing Sanofi’s blockbuster insulin drug Lantus, in South Korea on Thursday, intent on challenging the original drug’s dominance ...

Research and Markets has announced the addition of the "Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022" report to their offering. Global Biosimilar Insulin Market ...

The U.S. Food and Drug Administration approved last Wednesday the diabetes drug Basaglar, which is Eli Lilly's cheaper version of Sanofi’s insulin treatment Lantus. The insulin glargine drug is a long ...